open access

Vol 53, No 1 (2022)
Short communication
Submitted: 2021-09-07
Accepted: 2021-10-10
Published online: 2022-02-25
Get Citation

Ruxolitinib for steroid-refractory acute graft versus host disease: case series and literature review

Adrianna Spałek1, Krzysztof Woźniczka1, Anna Armatys1, Agata Wieczorkiewicz-Kabut1, Izabela Noster1, Grzegorz Helbig1
DOI: 10.5603/AHP.2022.0006
·
Acta Haematol Pol 2022;53(1):66-68.
Affiliations
  1. Katedra i Klinika Hematologii i Transplantacji Szpiku Śląskiego Uniwersytetu Medycznego w Katowicach

open access

Vol 53, No 1 (2022)
SHORT COMMUNICATION
Submitted: 2021-09-07
Accepted: 2021-10-10
Published online: 2022-02-25

Abstract

Not required

Abstract

Not required

Get Citation

Keywords

acute graft versus host disease; allogeneic hematopoietic stem cell transplantation; ruxolitinib; immunosuppression

About this article
Title

Ruxolitinib for steroid-refractory acute graft versus host disease: case series and literature review

Journal

Acta Haematologica Polonica

Issue

Vol 53, No 1 (2022)

Article type

Short communication

Pages

66-68

Published online

2022-02-25

Page views

676

Article views/downloads

114

DOI

10.5603/AHP.2022.0006

Bibliographic record

Acta Haematol Pol 2022;53(1):66-68.

Keywords

acute graft versus host disease
allogeneic hematopoietic stem cell transplantation
ruxolitinib
immunosuppression

Authors

Adrianna Spałek
Krzysztof Woźniczka
Anna Armatys
Agata Wieczorkiewicz-Kabut
Izabela Noster
Grzegorz Helbig

References (15)
  1. Martin PJ, Rizzo JD, Wingard JR, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012; 18(8): 1150–1163.
  2. Ruutu T, Gratwohl A, de Witte T, et al. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. Bone Marrow Transplant. 2014; 49(2): 168–173.
  3. Przepiorka D, Luo L, Subramaniam S, et al. FDA approval summary: ruxolitinib for treatment of steroid-refractory acute graft-versus-host disease. Oncologist. 2020; 25(2): e328–e334.
  4. Zeiser R, von Bubnoff N, Butler J, et al. REACH2 Trial Group. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med. 2020; 382(19): 1800–1810.
  5. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995; 15(6): 825–828.
  6. Elli EM, Baratè C, Mendicino F, et al. Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib. Front Oncol. 2019; 9: 1186.
  7. Spoerl S, Mathew NR, Bscheider M, et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood. 2014; 123(24): 3832–3842.
  8. Jagasia M, Perales MA, Schroeder M, et al. Results from REACH1, a single-arm phase 2 study of ruxolitinib in combination with corticosteroids for the treatment of steroid-refractory acute graft-vs-host disease. Blood. 2018; 132(Suppl 1): 601–601.
  9. Gomez VE, Garcia-Gutierrez V, Corral LL, et al. Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter study. Bone Marrow Transplant. 2020; 55(3): 641–648.
  10. Abedin S, McKenna E, Chhabra S, et al. Efficacy, toxicity, and infectious complications in ruxolitinib-treated patients with corticosteroid-refractory graft-versus-host disease after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019; 25(8): 1689–1694.
  11. Chang YJ, Zhao XY, Huang XJ. Strategies for enhancing and preserving anti-leukemia effects without aggravating gaft-versus-host disease. Front Immunol. 2018; 9: 3041.
  12. Choi J, Cooper ML, Alahmari B, et al. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect. PLoS One. 2014; 9(10): e109799.
  13. Zeiser R, Burchert A, Lengerke C, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015; 29(10): 2062–2068.
  14. Mohty M, Holler E, Jagasia M, et al. Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness. Blood. 2020; 136(17): 1903–1906.
  15. Liu Y, Fan Yi, Zhang W, et al. Efficiency and toxicity of ruxolitinib as the salvage treatment in steroid-refractoryc acute graft-versus-host disease after haplo-identical stem cell transplantation. Transplant Cell Ther. 2021; 27(4): 332.e1–332.e8.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl